Share
iStent® technology, has revolutionised the treatment of glaucoma in Australia since its introduction in 2016. As the tiniest implantable device in the human body, it has been a game-changer for patients diagnosed with glaucoma by effectively reducing eye pressure and medication burden. With over 1 million successful implantations worldwide, its impact is truly remarkable.
Glaukos is pleased to announce the new addition to the iStent family – iStent infinite® is now available.
iStent infinite is designed to provide foundational, 24/7 therapy that gives ophthalmologists the power to deliver optimised treatment for patients with primary open angle glaucoma, currently treated with glaucoma medication including those who have failed prior medical or surgical intervention, while minimising the unwanted side effects of more invasive treatment options
iStent infinite can be implanted in combination with cataract surgery or as a standalone procedure.
iStent infinite is approved by the Therapeutics & Drug Administration and on the Prosthesis List.
To find out more about iStent infinite please speak with your ophthalmologist.
An Australian study found that visual field testing for glaucoma can be quite stressful and physically uncomfortable, but small changes like allowing breaks and improving patient education could make the experience better.
A study from China suggests that high levels of 'good' cholesterol (HDL) may increase the risk of glaucoma, while higher levels of 'bad' cholesterol (LDL) and triglycerides could lower the risk, challenging traditional views on cholesterol and eye health.
The Snow Medical Research Foundation and the University of Sydney have launched the AU$50 million Snow Vision Accelerator programme to develop innovative therapies for glaucoma.